News

Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.

MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.

A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.

A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.

A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.

A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.

According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.

On March 19, 2024, the US FDA granted accelerated approval to ponatinib with chemotherapy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

The study results underscore the positive benefit-risk profile of pembrolizumab in combination with CCRT, offering a promising therapeutic approach for improving outcomes and maintaining quality of life in this patient population.